Evidence map›Paper›PMID 41571296›Full record

ArticleJournal for immunotherapy of cancer2026

Intrapatient variation in PD-L1 expression and tumor mutational burden and implications for outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.

Gege Li, Jiashuai Xu, Xiaohan Tian, Jingyi Xiao, Junqi Long, Yining Chen, Wenzhi Shen, Shuangtao Zhao

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gege LiDepartment of Breast and Thyroid Surgery, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Jiashuai XuDepartment of Breast and Thyroid Surgery, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Xiaohan TianDepartment of Breast and Thyroid Surgery, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Jingyi XiaoDepartment of Breast and Thyroid Surgery, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Junqi LongCollege of Computer Science, Beijing University of Technology, Beijing, China.
Yining ChenDepartment of Breast and Thyroid Surgery, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Wenzhi ShenShandong Provincial Precision Medicine Laboratory for Chronic Non-Communicable Diseases, Jining Medical University, Jining, China zst-1981@163.com shenwenzhi2011@126.com.
Shuangtao ZhaoDepartment of Breast and Thyroid Surgery, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China zst-1981@163.com shenwenzhi2011@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent study by Di Federico

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsBiomarkers, TumorHumansImmunotherapyMutationB7-H1 AntigenBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsBiomarkerImmune Checkpoint InhibitorImmunotherapyLung CancerTumor mutation burden - TMB

Identifiers

PMID41571296
PMCPMC12829371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.